Company: SMNR
Filing Date: 2025-08-08
Form Type: S-4/A
Source: 0001193125-25-177097
Chunk: 564

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-08
Form: S-4/A
Chunk 564
---
-----|-------:|:--|
| Operating activities                                  |     | $               | (399 | ) |     | $    | (2,159 | ) |
| Financing activities                                  |     |                 |  394 |   |     |      |  2,164 |   |
| Net change in cash and cash equivalents               |     | $               |   (5 | ) |     | $    |      5 |   |

|                                                       |     | Year Ended   
 December 31, |   2024 |   |     |   |   2023 |   |
|:------------------------------------------------------|:----|:-------------|-------:|:--|:----|:--|-------:|:--|
| Net cash and cash equivalents (used for) provided by: |     |              |        |   |     |   |        |   |
| Operating activities                                  |     | $            | (4,891 | ) |     | $ | (1,677 | ) |
| Financing activities                                  |     |              |  4,891 |   |     |   |  1,661 |   |
| Net change in cash and cash equivalents               |     | $            |      — |   |     | $ |    (16 | ) |

**Cash Flows from Operating Activities For the three months ended March 31, 2025, net cash used for operating activities was approximately $0.4 million, attributable to our net loss of $0.7 million, partially offset by stock-based compensation of $0.1 million and changes in operating assets and liabilities that provided $0.2 million of cash. For the three months ended March 31, 2024, net cash used for operating activities was approximately $2.1 million, attributable to our net loss of $1.5 million and changes in operating assets and liabilities that used $0.8 million of cash, partially offset by stock-based compensation of $0.2 million. For the year ended December 31, 2024, net cash used for operating activities was approximately $4.9 million, attributable to our net loss of $4.7 million and changes in operating assets and liabilities that used $0.9 million of cash, partially offset by stock-based compensation of $0.7 million. For the year ended December 31, 2023, net cash used for operating activities was approximately $1.7 million, attributable to our net loss